Scilex Holding Company is a specialty pharmaceutical firm focused on the commercialization, licensing and distribution of branded products for the management of acute and chronic pain. Established through a series of strategic acquisitions and internal development efforts, the company concentrates on non-opioid, topical and systemic therapies designed to address unmet needs in neuropathic and musculoskeletal pain. Scilex partners with healthcare providers, pharmacies and specialty distributors to bring its portfolio to patients across the United States.
The company’s flagship product, ZTlido® (lidocaine topical system 1.8%), is an FDA-approved prescription patch indicated for the relief of pain associated with postherpetic neuralgia. Leveraging a proprietary drug delivery matrix, ZTlido provides consistent, localized administration of lidocaine over a 12-hour wear period. Since its commercial launch, Scilex has built a dedicated field force and market access team to support product uptake among dermatologists, neurologists and pain specialists.
Beyond its marketed offering, Scilex is advancing a pipeline of follow-on pain management candidates and exploring label extensions for existing assets. The company evaluates opportunities to in-license complementary technologies and is conducting clinical trials aimed at expanding the indication of its lead topical therapy to other neuropathic pain syndromes and musculoskeletal conditions.
Headquartered in King of Prussia, Pennsylvania, Scilex operates within the U.S. regulatory framework under the oversight of the Food and Drug Administration. The company’s leadership team brings experience in pharmaceutical development, commercial operations and regulatory affairs, supporting its mission to deliver innovative, non-addictive pain treatments to patients in need.
AI Generated. May Contain Errors.
